Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

Recruiting

Phase 2

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

Sponsor:

Mayo Clinic

Code:

NCT05167721

Conditions

Multiple System Atrophy

Eligibility Criteria

Sex: All

Age: 30 - 70

Healthy Volunteers: Not accepted

Interventions

Autologous Mesenchymal Stem Cells

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2025-03-14.